371 related articles for article (PubMed ID: 27300552)
1. Clinicopathologic and Molecular Features of Colorectal Adenocarcinoma with Signet-Ring Cell Component.
Wei Q; Wang X; Gao J; Li J; Li J; Qi C; Li Y; Li Z; Shen L
PLoS One; 2016; 11(6):e0156659. PubMed ID: 27300552
[TBL] [Abstract][Full Text] [Related]
2. [Comparative analysis of real-time quantitative PCR-Sanger sequencing method and TaqMan probe method for detection of KRAS/BRAF mutation in colorectal carcinomas].
Zhang X; Wang Y; Gao N; Wang J
Zhonghua Bing Li Xue Za Zhi; 2014 Feb; 43(2):77-82. PubMed ID: 24742565
[TBL] [Abstract][Full Text] [Related]
3. Clinicopathologic and molecular features of sporadic early-onset colorectal adenocarcinoma: an adenocarcinoma with frequent signet ring cell differentiation, rectal and sigmoid involvement, and adverse morphologic features.
Chang DT; Pai RK; Rybicki LA; Dimaio MA; Limaye M; Jayachandran P; Koong AC; Kunz PA; Fisher GA; Ford JM; Welton M; Shelton A; Ma L; Arber DA; Pai RK
Mod Pathol; 2012 Aug; 25(8):1128-39. PubMed ID: 22481281
[TBL] [Abstract][Full Text] [Related]
4. Loss of heterozygosity, aberrant methylation, BRAF mutation and KRAS mutation in colorectal signet ring cell carcinoma.
Kakar S; Deng G; Smyrk TC; Cun L; Sahai V; Kim YS
Mod Pathol; 2012 Jul; 25(7):1040-7. PubMed ID: 22522845
[TBL] [Abstract][Full Text] [Related]
5. RAS status in Korean patients with stage III and IV colorectal cancer.
Lee WS; Lee JN; Baek JH; Park YH
Clin Transl Oncol; 2015 Sep; 17(9):751-6. PubMed ID: 25997687
[TBL] [Abstract][Full Text] [Related]
6. Clinicopathological and Corresponding Genetic Features of Colorectal Signet Ring Cell Carcinoma.
Tajiri K; Sudou T; Fujita F; Hisaka T; Kinugasa T; Akagi Y
Anticancer Res; 2017 Jul; 37(7):3817-3823. PubMed ID: 28668881
[TBL] [Abstract][Full Text] [Related]
7. Colorectal poorly differentiated neuroendocrine carcinomas frequently exhibit BRAF mutations and are associated with poor overall survival.
Olevian DC; Nikiforova MN; Chiosea S; Sun W; Bahary N; Kuan SF; Pai RK
Hum Pathol; 2016 Mar; 49():124-34. PubMed ID: 26826419
[TBL] [Abstract][Full Text] [Related]
8. Prognostic significance and molecular features of signet-ring cell and mucinous components in colorectal carcinoma.
Inamura K; Yamauchi M; Nishihara R; Kim SA; Mima K; Sukawa Y; Li T; Yasunari M; Zhang X; Wu K; Meyerhardt JA; Fuchs CS; Harris CC; Qian ZR; Ogino S
Ann Surg Oncol; 2015 Apr; 22(4):1226-1235. PubMed ID: 25326395
[TBL] [Abstract][Full Text] [Related]
9. Distinct molecular features of colorectal carcinoma with signet ring cell component and colorectal carcinoma with mucinous component.
Ogino S; Brahmandam M; Cantor M; Namgyal C; Kawasaki T; Kirkner G; Meyerhardt JA; Loda M; Fuchs CS
Mod Pathol; 2006 Jan; 19(1):59-68. PubMed ID: 16118624
[TBL] [Abstract][Full Text] [Related]
10. Mutations of KRAS, NRAS, BRAF, EGFR, and PIK3CA genes in urachal carcinoma: Occurence and prognostic significance.
Módos O; Reis H; Niedworok C; Rübben H; Szendröi A; Szász MA; Tímár J; Baghy K; Kovalszky I; Golabek T; Chlosta P; Okon K; Peyronnet B; Mathieu R; Shariat SF; Hollósi P; Nyirády P; Szarvas T
Oncotarget; 2016 Jun; 7(26):39293-39301. PubMed ID: 27283768
[TBL] [Abstract][Full Text] [Related]
11. Primary signet ring cell carcinoma of colorectum: an age- and sex-matched controlled study.
Tung SY; Wu CS; Chen PC
Am J Gastroenterol; 1996 Oct; 91(10):2195-9. PubMed ID: 8855747
[TBL] [Abstract][Full Text] [Related]
12. Extended RAS and BRAF Mutation Analysis Using Next-Generation Sequencing.
Sakai K; Tsurutani J; Yamanaka T; Yoneshige A; Ito A; Togashi Y; De Velasco MA; Terashima M; Fujita Y; Tomida S; Tamura T; Nakagawa K; Nishio K
PLoS One; 2015; 10(5):e0121891. PubMed ID: 25954997
[TBL] [Abstract][Full Text] [Related]
13. The Coexistence of RAS and BRAF Mutations in Metastatic Colorectal Cancer: A Case Report and Systematic Literature Review.
Afrăsânie VA; Gafton B; Marinca MV; Alexa-Stratulat T; Miron L; Rusu C; Ivanov AV; Balan GG; Croitoru AE
J Gastrointestin Liver Dis; 2020 Jun; 29(2):251-256. PubMed ID: 32530992
[TBL] [Abstract][Full Text] [Related]
14. Association between clinicopathological characteristics and RAS mutation in colorectal cancer.
Rimbert J; Tachon G; Junca A; Villalva C; Karayan-Tapon L; Tougeron D
Mod Pathol; 2018 Mar; 31(3):517-526. PubMed ID: 29052598
[TBL] [Abstract][Full Text] [Related]
15. Distinct Histopathologic and Molecular Alterations in Inflammatory Bowel Disease-Associated Intestinal Adenocarcinoma: c-MYC Amplification is Common and Associated with Mucinous/Signet Ring Cell Differentiation.
Hartman DJ; Binion DG; Regueiro MD; Miller C; Herbst C; Pai RK
Inflamm Bowel Dis; 2018 Jul; 24(8):1780-1790. PubMed ID: 29788391
[TBL] [Abstract][Full Text] [Related]
16. FOLFOX4 Plus Cetuximab for Patients With Previously Untreated Metastatic Colorectal Cancer According to Tumor RAS and BRAF Mutation Status: Updated Analysis of the CECOG/CORE 1.2.002 Study.
Kaczirek K; Ciuleanu TE; Vrbanec D; Marton E; Messinger D; Liegl-Atzwanger B; Wrba F; Knittelfelder R; Lindner E; Zielinski CC; Streubel B; Brodowicz T
Clin Colorectal Cancer; 2015 Jun; 14(2):91-8. PubMed ID: 25666295
[TBL] [Abstract][Full Text] [Related]
17. Mutation Analysis of KRAS and BRAF Genes in Metastatic Colorectal Cancer: a First Large Scale Study from Iran.
Koochak A; Rakhshani N; Karbalaie Niya MH; Tameshkel FS; Sohrabi MR; Babaee MR; Rezvani H; Bahar B; Imanzade F; Zamani F; Khonsari MR; Ajdarkosh H; Hemmasi G
Asian Pac J Cancer Prev; 2016; 17(2):603-8. PubMed ID: 26925650
[TBL] [Abstract][Full Text] [Related]
18. Metastatic colorectal carcinoma with signet-ring cells: Clinical, histological and molecular description from an Association des Gastro-Entérologues Oncologues (AGEO) French multicenter retrospective cohort.
Allart M; Leroy F; Kim S; Sefrioui D; Nayeri M; Zaanan A; Rousseau B; Ben Abdelghani M; de la Fouchardière C; Cacheux W; Legros R; Louafi S; Tougeron D; Bouché O; Fares N; Roquin G; Bignon AL; Maillet M; Pozet A; Hautefeuille V;
Dig Liver Dis; 2022 Mar; 54(3):391-399. PubMed ID: 34384712
[TBL] [Abstract][Full Text] [Related]
19. Differences in Pathology and Mutation Status Among Colorectal Cancer Patients Younger Than, Older Than, and of Screening Age.
Pereira AAL; Fernandes GDS; Braga GTP; Marchetti KR; Mascarenhas CDC; Gumz B; Crosara M; Dib L; Girardi D; Barrichello A; Seidler H
Clin Colorectal Cancer; 2020 Dec; 19(4):e264-e271. PubMed ID: 32741580
[TBL] [Abstract][Full Text] [Related]
20. Role of NRAS mutations as prognostic and predictive markers in metastatic colorectal cancer.
Schirripa M; Cremolini C; Loupakis F; Morvillo M; Bergamo F; Zoratto F; Salvatore L; Antoniotti C; Marmorino F; Sensi E; Lupi C; Fontanini G; De Gregorio V; Giannini R; Basolo F; Masi G; Falcone A
Int J Cancer; 2015 Jan; 136(1):83-90. PubMed ID: 24806288
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
